American Heart Journal
Volume 149, Issue 2 , Pages 234-239 , February 2005

Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial

  • John J.P. Kastelein, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationReprint requests: John J.P. Kastelein, MD, PhD, Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
    • ,
  • Philip T. Sager, MD

      Affiliations

    • Schering-Plough Research Institute, Kenilworth, NJ
    • ,
  • Eric de Groot, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Enrico Veltri, MD

      Affiliations

    • Schering-Plough Research Institute, Kenilworth, NJ

Received 28 January 2004 ,Accepted 29 June 2004.

References 

  1. Durrington P. Dyslipidaemia. Lancet. 2003;362:717–731
  2. LaRosa JC. Understanding risk in hypercholesterolemia. Clin. Cardiol. 2003;26(Suppl. 1):13–16
  3. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–2346
  4. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423–1426
  5. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  6. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577–581
  7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  8. de Backer G, Ambrosini E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur. J. Cardiovasc. Prev. Rehabil. 2003;10:S1–S10
  9. Stone N. Combination therapy: its rationale and the role of ezetimibe. Eur. Heart J. 2002;4(Suppl. J):J19–J22
  10. van Heek M, Davis H. Pharmacology of ezetimibe. Eur. Heart J. 2002;4(Suppl. J):J5–J8
  11. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 2002;40:2125–2134i
  12. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am. J. Cardiol. 2003;91:418–424
  13. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409–2415
  14. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur. Heart J. 2003;24:717–728
  15. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 2002;90:1084–1091
  16. Sager PT, Melani L, Lipka L, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am. J. Cardiol. 2003;92:1414–1418
  17. Mack WJ, LaBree L, Liu C-R, et al. Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Atherosclerosis. 2000;150:371–379
  18. Cheng K-S, Mikhailidis DP, Hamilton G, et al. A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc. Res. 2002;54:528–538
  19. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 1998;128:262–269
  20. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am. J. Cardiol. 1995;75:455–459
  21. de Groot E, Jukema JW, Montauban van Swinjndregt AD, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J. Am. Coll. Cardiol. 1998;31:1561–1567
  22. Kroon AA, van Asten WN, Stalenhoef AF. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann. Intern. Med. 1996;125:945–954
  23. Kroon AA, Aengevaeren WR, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996;93:1826–1835
  24. Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758–1764
  25. Marks D, Thorogood M, Neil HA, et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolemia. Atherosclerosis. 2003;168:1–14
  26. Nolting PR, de Groot E, Zwinderman AH, et al. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch. Intern. Med. 2003;163:1837–1841
  27. Wendelhag I, Wiklund O, Wikstrand J. On quantifying plaque size and intima-media thickness in carotid and femoral arteries. Comments on results from a prospective ultrasound study in patients with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 1996;16:843–850
  28. Wittekoek ME, de Groot E, Prins MH, et al. Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. Atherosclerosis. 1999;146:271–279

PII: S0002-8703(04)00550-2

doi: 10.1016/j.ahj.2004.06.024

American Heart Journal
Volume 149, Issue 2 , Pages 234-239 , February 2005

Article Tools

* Image Usage & Resolution